Company Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications.
Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.
The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy.
Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia.
Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
| Country | United States |
| IPO Date | May 14, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Les D. Funtleyder |
Contact Details
Address: 545 Fifth Avenue New York, New York United States | |
| Website | https://www.appliedtherapeutics.com |
Stock Details
| Ticker Symbol | APLT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001697532 |
| CUSIP Number | 03828A101 |
| ISIN Number | US03828A1016 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Les D. Funtleyder | Interm Chief Executive Officer, Chief Financial Officer, Principal Financial Officer & Director |
| Constantine Chinoporos | Chief Operating Officer & Chief Business Officer |
| Catherine Thorpe | Chief Accounting Officer |
| Corwin Dale Hooks | Chief Commercial Officer |
| Dr. Riccardo Perfetti M.D., Ph.D. | Chief Medical Officer |
| John H. Johnson | Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 4 | Filing |
| Dec 20, 2024 | 4 | Filing |
| Dec 20, 2024 | 3 | Filing |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Dec 06, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Dec 02, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |